Viatris's VR-205: A New Hope for IgA Nephropathy Patients in Japan

PITTSBURGH and TOKYO – June 29, 2026 – Global healthcare company Viatris Inc. today announced a significant breakthrough for patients with primary Immunoglobulin A Nephropathy (IgAN) in Japan. The company revealed positive top-line results from its Phase 3 clinical trial of VR-205 (a targeted-release budesonide formulation), a novel treatment for this progressive autoimmune kidney disease. The study successfully met its primary and key secondary endpoints, demonstrating both clinically meaningful efficacy and a favorable safety profile in Japanese adults.

This promising development positions VR-205, already marketed as Tarpeyo® in the United States and Kinpeygo® in Europe, to potentially become the first IgAN-specific, targeted-release oral therapy available in Japan. With plans to submit a New Drug Application (NDA) by the end of 2026, Viatris is on a clear path to introducing a new standard of care in a nation that bears the world's highest incidence of IgAN.

A Landmark Clinical Success in Japan

The Phase 3 trial (VR-205A-01-CAZ-3001) was a multicenter, open-label study designed specifically for the Japanese population. Over a nine-month treatment period, 39 adult patients with primary IgAN received a daily 16 mg dose of VR-205. The results were statistically significant and aligned with findings from the larger global studies of the drug.

The study's primary endpoint was a reduction in proteinuria, a key marker of kidney damage. VR-205 achieved a 33.75 percent reduction in the geometric mean urine protein-to-creatinine ratio (UPCR) at nine months compared to baseline. This substantial decrease underscores the drug's ability to directly address the disease's impact on kidney function.

Beyond the primary goal, the trial also met its key secondary endpoints, providing a comprehensive picture of the therapeutic benefit. Patients treated with VR-205 showed significant improvements in their estimated glomerular filtration rate (eGFR), a measure of how well the kidneys are filtering waste from the blood. Additionally, the treatment led to reductions in serum creatinine and urine albumin-to-creatinine ratio (UACR), further supporting its positive effect on kidney health. Crucially, no participant in the study progressed to severe renal impairment, requiring dialysis or a kidney transplant, by the end of the trial. The treatment was also well-tolerated, with a safety profile consistent with the known effects of this formulation in non-Japanese patients.

"We are pleased with these top-line results, which highlight VR-205 as a potentially meaningful, disease-modifying treatment option for patients with primary IgAN," said Viatris Chief R&D Officer Philippe Martin. "In Japan, where IgAN incidence is the highest globally, VR-205 could become the first IgAN-specific, targeted-release budesonide oral therapy."

Addressing a Critical Unmet Need in IgAN Treatment

IgA Nephropathy, also known as Berger's disease, is a progressive, immune-mediated condition where the antibody immunoglobulin A builds up in the kidneys, causing inflammation that hampers their ability to filter waste from the blood. It is the most common form of primary glomerulonephritis worldwide, but its prevalence is particularly acute in Japan. The country reports 39 to 45 new cases per million people annually, the highest rate globally, with the disease often diagnosed in adults between 30 and 39 years old.

In Japan, IgAN is designated an "intractable disease," reflecting the severe challenges it poses. Despite the risk of progression to end-stage renal disease (ESRD) in 15-20 percent of patients within a decade, curative treatments have remained elusive. Patients who reach ESRD face a lifetime of dialysis or the uncertainty of a kidney transplant, contributing to a national maintenance hemodialysis cost of approximately JPY 1.5 trillion per year.

Current treatment standards largely revolve around supportive care, such as blood pressure medications to reduce proteinuria, or the use of non-specific systemic corticosteroids, which can carry a heavy burden of side effects. VR-205 represents a paradigm shift. Its targeted-release formulation is designed to deliver budesonide directly to the Peyer's patches in the lower small intestine (ileum), the area believed to be central to the production of the pathogenic IgA antibodies that drive the disease. This localized action aims to reduce the production of these antibodies at their source, thereby modifying the disease's course with a more targeted approach.

"Primary IgAN is a designated intractable disease in Japan, and remains a significant unmet need, with no curative treatment despite the risk of progression to end-stage renal disease," commented Yuko Asami, Head of R&D for Viatris Japan. "These top-line results mark an important step toward expanding treatment options for patients and healthcare providers."

Viatris's Strategic Move in the Japanese Market

The success of the VR-205 trial is a cornerstone of Viatris's broader strategy to build a differentiated and innovative pharmaceutical portfolio in Japan. The company, formed through a merger and known for its vast portfolio of generics and established brands, is making deliberate inroads into specialty medicines that address significant unmet needs. This move is reinforced by a 2022 exclusive license agreement with the drug's original developer, Calliditas Therapeutics AB, granting Viatris the rights to commercialize VR-205 in Japan.

The potential launch of VR-205 is poised to have a significant commercial impact. While the global IgAN treatment landscape is becoming more competitive with entrants like Travere Therapeutics' Filspari and a robust pipeline from Novartis, VR-205's targeted mechanism and strong clinical data position it favorably. Its prior full FDA approval in the U.S. and marketing authorization in Europe lend substantial credibility and a proven track record.

This development aligns with the company's strong financial footing, having exceeded analyst expectations in recent quarters. The introduction of a novel, high-value specialty drug in a key market like Japan could further bolster its revenue streams and solidify its reputation as a key player in innovative therapies. The success of this "bridging study" in Japan, which required a smaller patient cohort due to the extensive data from the global NefIgArd trial, demonstrates an efficient and effective clinical development strategy.

Global Implications and the Path Forward

The positive outcome in Japan is not an isolated event but rather the latest chapter in a global success story for this targeted therapy. The drug's full approval from the U.S. FDA in December 2023 was a landmark moment, granted based on its proven ability to significantly slow the loss of kidney function in adults with IgAN at risk of progression. The global Phase 3 NefIgArd study showed that, over a two-year period, patients treated with the drug experienced 50% less deterioration in kidney function compared to those on a placebo.

Validating these robust results within the Japanese population is a critical step. It not only brings a much-needed therapy closer to patients in a high-incidence region but also enriches the global understanding of IgAN treatment. Success in Japan could inform and accelerate therapeutic developments worldwide, particularly in managing rare and orphan diseases with distinct regional prevalences.

With the strength of this data, Viatris is confidently moving forward. The company's targeted submission of a New Drug Application to Japanese regulatory authorities by the end of 2026 sets a clear timeline for bringing this innovative treatment to the patients who have been waiting for a breakthrough.